T-Cell Lymphoma Pipeline: Over 90 Companies Developing New Drugs
A market analysis report details the landscape of T-cell lymphoma drug development, featuring over 90 companies and 90+ pipeline drug candidates across various clinical and non-clinical stages.
A new market analysis report offers comprehensive insights into the T-cell lymphoma (TCL) drug development pipeline, identifying over 90 companies and 90+ potential therapeutic candidates.
DelveInsight's "T-Cell Lymphoma Pipeline Insight, 2026," released on October 16, 2026, maps the current research and development activities. The report covers drug profiles in clinical and non-clinical stages, along with therapeutic assessments based on product type, stage, route of administration, and molecule type. It also identifies inactive pipeline products.
Recent developments mentioned include the National Cancer Institute (NCI) updating a Phase I trial for azacitidine in combination with abatacept, and a strategic partnership between Innate Pharma and Sobi advancing lacutamab towards a Phase III trial. Additionally, the Lymphoma Research Foundation launched an international consortium to bolster research collaboration.
Key companies highlighted include Soligenix, CStone Pharmaceuticals, Genor Biopharma, and Innate Pharma. Promising therapies in development include rogolinolisib, golcadomide, and azacitidine. T-cell lymphomas are a group of rare and often aggressive non-Hodgkin lymphomas, typically affecting older adults.